dc.contributor.author | Nikolopoulos, Georgios K. | en |
dc.contributor.author | Bonovas, Stefanos | en |
dc.contributor.author | Tsantes, Argirio E. | en |
dc.contributor.author | Sitaras, N. M. | en |
dc.creator | Nikolopoulos, Georgios K. | en |
dc.creator | Bonovas, Stefanos | en |
dc.creator | Tsantes, Argirio E. | en |
dc.creator | Sitaras, N. M. | en |
dc.date.accessioned | 2018-06-22T09:54:04Z | |
dc.date.available | 2018-06-22T09:54:04Z | |
dc.date.issued | 2009 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42181 | |
dc.description.abstract | Despite the considerable progress in antiretroviral therapy, the eradication of HIV-1 remains unfeasible. Therefore, novel agents are under investigation. The aim of this review is to summarize the conventional compounds, to describe the recently approved agents, and to take a comprehensive look at the clinically relevant findings of current research. © 2009 Bentham Science Publishers Ltd. | en |
dc.language.iso | eng | en |
dc.source | Mini-Reviews in Medicinal Chemistry | en |
dc.subject | 2 | |
dc.subject | 3 | |
dc.subject | 5 | |
dc.subject | United states | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Clinical trial | en |
dc.subject | Review | en |
dc.subject | Lamivudine | en |
dc.subject | Unindexed drug | en |
dc.subject | Zidovudine | en |
dc.subject | Receptors | en |
dc.subject | Unclassified drug | en |
dc.subject | Placebo | en |
dc.subject | Hiv infections | en |
dc.subject | Drug research | en |
dc.subject | Drug withdrawal | en |
dc.subject | Drug approval | en |
dc.subject | Food and drug administration | en |
dc.subject | Unspecified side effect | en |
dc.subject | Animals | en |
dc.subject | Highly active antiretroviral therapy | en |
dc.subject | Hiv | en |
dc.subject | Anti-hiv agents | en |
dc.subject | Human immunodeficiency virus 1 | en |
dc.subject | Indinavir | en |
dc.subject | Hiv-1 | en |
dc.subject | Antiretrovirus agent | en |
dc.subject | Emtricitabine | en |
dc.subject | Virus replication | en |
dc.subject | Acquired immune deficiency syndrome | en |
dc.subject | 4 tetrahydroquinoline | en |
dc.subject | 6 dihydroazacitidine | en |
dc.subject | 8 [(4 aminobutyl)(2 benzimidazolylmethyl)amino] 1 | en |
dc.subject | Amprenavir phosphate | en |
dc.subject | Antiretrovirals | en |
dc.subject | Antiviral resistance | en |
dc.subject | Apricitabine | en |
dc.subject | Atazanavir | en |
dc.subject | Bevirimat | en |
dc.subject | Ccr5 | en |
dc.subject | Cxcr4 | en |
dc.subject | Delavirdine | en |
dc.subject | Drug substitution | en |
dc.subject | Efavirenz | en |
dc.subject | Elvitegravir | en |
dc.subject | Elvucitabine | en |
dc.subject | Eradication therapy | en |
dc.subject | Etravirine | en |
dc.subject | Human immunodeficiency virus 1 infection | en |
dc.subject | Ibalizumab | en |
dc.subject | Integrase inhibitors | en |
dc.subject | K 1212 | en |
dc.subject | Lopinavir plus ritonavir | en |
dc.subject | Maraviroc | en |
dc.subject | Maturation inhibitors | en |
dc.subject | Nelfinavir | en |
dc.subject | Nevirapine | en |
dc.subject | Pro 140 | en |
dc.subject | Protease inhibitors | en |
dc.subject | Raltegravir | en |
dc.subject | Reverse transcriptase inhibitors | en |
dc.subject | Rilpivirine | en |
dc.subject | Ritonavir | en |
dc.subject | Saquinavir | en |
dc.subject | Tipranavir | en |
dc.subject | Vicriviroc | en |
dc.subject | Efavirenz plus emtricitabine plus tenofovir disoproxil | fr |
dc.title | HIV/AIDS: Recent advances in antiretroviral agents | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 9 | |
dc.description.issue | 8 | |
dc.description.startingpage | 900 | |
dc.description.endingpage | 910 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Nikolopoulos, Georgios K.[0000-0002-3307-0246] | |
dc.contributor.orcid | Bonovas, Stefanos [0000-0001-6102-6579] | |
dc.gnosis.orcid | 0000-0002-3307-0246 | |
dc.gnosis.orcid | 0000-0001-6102-6579 | |